News >

Novel Agents May Change Paradigm for Advanced HER2+ Breast Cancer

Meir Rinde
Published: Monday, Mar 11, 2019

Sara A. Hurvitz, MD

Sara A. Hurvitz, MD
The treatment of patients with advanced HER2-positive breast cancer could be reshaped in the next several years as clinical trials of a number of exciting new drugs begin to yield results, according to Sara A. Hurvitz, MD.

Hurvitz noted that lapatinib-based therapies continue to be used after T-DM1.


In terms of development, the most advanced of the new HER2 options is neratinib, which was approved in July 2017 for extended adjuvant treatment of adults with early-stage HER2-positive breast cancer following postoperative trastuzumab. In the ExteNET trial, the rate of invasive disease-free survival (iDFS) at 24 months was 94.2% in patients treated with neratinib compared with 91.9% in those receiving placebo (HR, 0.66; 95% CI, 0.49-0.90; P = .008).3
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication